Randomized Phase 2 Study Of PF-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Gedatolisib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 16 Jul 2016 This trial has been completed in Belgium (2016-04-06) as per European Clinical Trials Database record.
- 04 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.